REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Investors who purchased Regeneron Pharmaceuticals, Inc. securities between August 1, 2025 and May 15, 2026, inclusive, are encouraged to contact the Schall Law Firm before September 14, 2026. The lawsuit alleges that Regeneron made false and misleading statements to the market regarding its Phase III Fianlimab-Libtayo Study, utilizing flawed statistical assumptions and failing to demonstrate clinical differentiation from other therapies. This led to investor damages when the truth was revealed.